Ian Kunkler Research Group

Clinical and Translational Studies of Breast Radiotherapy

Professor Ian Kunkler

Honorary Professor of Clinical Oncology

Contact details

Research in a Nutshell 

I lead national and international clinical/translational trials assessing the impact of adjuvant radiotherapy (RT) on loco-regional recurrence, quality of life and health economics after mastectomy (BIG 2.04 MRC SUPREMO), and, in older patients, after breast conserving surgery (BCS) [PRIME 2] on local control in early breast cancer . I am CI for the UK arm of BIG 3-07 DCIS boost trial evaluating the role of additional radiation after breast conserving surgery  and postoperative breast radiotherapy  for non low risk DCIS.

I am interested in drug-radiation combinations targeting pH regulatory mechanisms (eg CA1X, NHE1) of breast cancer cells  as PI in METOXIA, an EU (FP7) project on translating the hypoxic microenvironment,(IMPACT- Implantable Microsystems for personalised anti-cancer treatment) led by Professor Alan Murray (Engineering) developing real time ‘lab-on-chip’ biosensors of tumour biology to identify areas of hypoxia in murine and veterinary animal models to enable selective delivery of  radiation dose to hypoxic subregions to improve local control (www.nutshell-videos.ed.ac.uk/alan-murray-sensors-in-tumours/) in partnership with ECRC, Chemistry, Roslin Institute, Innogen Institute and Heriot Watt University.

I am  interested in understanding outcomes of  rare cancers in Europe as co-PI for the EU funded RARECARE (FP6) and RARECARENet (FP7).

People

NameRole
Professor Ian KunklerConsultant Clinical Oncologist, Professor of Clinical Oncology and Group Leader
Dr Karen TaylorGroup Leader, Translational Pathology Group, UoE

2026 Honoree, 2026 TIME 100 list of most influential health professionals for SUPREMO trial results (time.com)[see Key publications]

2013:      Rohan Williams Travelling Professorship to Australia and New Zealand, Royal College of Radiology and Royal Australian and New Zealand College of Radiology

2010:      ESTRO Professorship, ALATRO ESTRO, Breast Oncology Course, Cordoba, Argentina 18-20 October 2010.

2006:      P5 Excellence in Oncology, Oncology Team of the Year Award of the British Oncological Association for the TELEMAM trial (Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, Bowman A, Neades G, Walls ADF, Chetty U, Dixon JM, Smith ME, Gardner TW, Macnab),2000:           

2000:      Cochrane Shanks Jalil Travelling Professor of the Royal College of Radiologists to Egypt.

1999:      Honoured delegate, Annual Scientific meeting of the Societe Francaise de Radiotherapie Oncologique, Paris 25-26 November 1999.

1977:      Bentley Prize in Surgery, St. Bartholomew’s Hospital, London


Since 1992 I have been developing in Edinburgh a portfolio of collaborative clinical and laboratory research in breast cancer supported by peer reviewed funding. The focus has been on clinical trials of postoperative adjuvant irradiation, the assessment of the role of telemedicine in multidisciplinary decision making on primary treatment, and more recently this has included the role of carbonic anhydrase inhibitors in conjunction with radiotherapy in the pre-operative treatment of breast cancer and the development of real time biosensors of tumour biology to guide radiotherapy. 

1996-1998: £16,000 from the European Union (DGX111) on behalf of the British Oncological Association. Satellite broadcasting in Oncology.

Eurotransmed, medical television network provided satellite broadcasts in medicine and surgery from London to over 200 receiver sites in the UK and mainland Europe. A European Union grant was awarded to evaluate by questionnaire the educational value of 6 satellite broadcasts in oncology on behalf of the British Oncological Association. I was joint grantholder on behalf of the British Oncological Association in collaboration with the EORTC, European School of Oncology, and the University of Leeds. I wrote a summary of the evaluation for the project report to the European Union.

1996-1998: £42,000 from the Nancie Massey Trust. Optimisation of dose distribution within the intact breast in the management of early breast cancer.

Jointly with Dr A Redpath (Dept of Oncology Physics, Edinburgh).

Using compensators in two planes for tangential breast irradiation and three dimensional dosimetry based on multislice CT scans of the breast of women undergoing breast irradiation, we showed that it is possible to reduce the variation in dose distribution across the breast from 20% to as low as 5% (see publications).

1997-1999: £68,700 from the Robertson Trust (Glasgow) BRCA2 mutations and CYP17 polymorphisms in male breast cancer.

Principal grantholder (Robertson Trust Glasgow) (jointly with Professor M Steel (St. Andrews University), Professor A Wyllie (Cambridge University) and Professor M Hooper (Edinburgh University).

A study of mutations of the BRCA2 gene and polymorphisms of the CYP17 gene which codes for the P450 c17alpha enzyme involved in oestrogen synthesis among 64 male breast cancer patients treated in Edinburgh. Laboratory work was undertaken by Mr Ian Young, Surgical Research Fellow in the Molecular Medicine Centre, Edinburgh University.

1997-1999: £90,000 from the Scottish Executive Grant. Prospective audit of malignant spinal cord compression in Scotland.

Joint grantholder with Dr P Levack (Principal Investigator, Dundee), Dr R Grant (Edinburgh), Dr D Collie (Edinburgh), Professor R Rampling (Glasgow) and Professor A Munro (Dundee) for a prospective audit of malignant spinal cord compression in Scotland.

1998-2009: £847,453 from the Department of Health. Postoperative adjuvant irradiation for breast cancer in the elderly (Health Technology Assessment). PRIME trial.

Co-Chief Investigator (joint grantholder with Professor R Prescott, Edinburgh University) for a 6 year grant from the Department of Health (Health Technology Assessment) for a trial assessing the impact of postoperative adjuvant breast irradiation on the quality of life of women aged 65 or older at low risk of local recurrence after breast conserving surgery and adjuvant endocrine therapy. Co-grant holders: Professor D George (Glasgow University); Professor M Dixon (Edinburgh Breast Unit); Mr J Cairns (Aberdeen University) and Mr R Lindley (Edinburgh University). 

1999-2002: £158,000 from the Scottish Office (Dept of Health) Scottish Founder mutations in BRCA1 and BRCA2 and modifiers of genetic cancer risk.

Co-grant holder with Professor. M Steel (Principal Investigator, St. Andrews University), Mr A Thompson (Dundee University), Ms E Anderson (Edinburgh University).

2004-2005: £28,400 from the Robertson Trust. 

Study of genetic mutations in male breast cancer in collaboration with Professor M Steel, (St Andrews University), Professor A Wyllie (University of Cambridge) and Mr I Young (University of Edinburgh).

2005-2010: £144,639 from the Chief Scientist’s Office for administrative support as Chief Investigator of PRIME 2 trial.

The PRIME 2 trial assesses the input on local control in 1000 patients from the omission of postoperative radiotherapy in low risk older patients managed by breast conserving surgery and adjuvant endocrine therapy. Target accrual was increased to 1300 patients to reflect falling local recurrence rates after breast conserving surgery and postoperative radiotherapy. Revised target accrual was met in November 2009 on schedule.

Joint grantholders: Professor RJ Prescott (Edinburgh), Mr JM Dixon (Edinburgh), Professor A Rodger (Glasgow), Mr P Walsh (Inverness), Dr L Williams (Edinburgh).

2003-2006: 919,609 Euros from EUROCHIP 2 project on European health monitoring indicators for cancer. Joint grantholder with Dr Andrea Micheli (Principal Investigator, Milan).

The EUROCHIP 2 project builds on the EU funded EUROCHIP I project in which health monitoring indicators were agreed among 15 EU countries. It collected these indicators in all 25 EU countries. I chaired the Care and Treatment group.

2003-2006: £295,810 from Breakthrough and Cancer Research UK Genetic Breast Cancer Trial. Funded in March 2004. Co-applicant with Dr J Mackay (Principal Investigator, Imperial College, London) and others.

The study assessed the role of taxanes in metastatic breast cancer in patients with BRCAI and BRCA2 mutations.

2005-2023: £2,121,597 from the Medical Research Council Health Service and Public Health Research Board. 

Chief investigator of MRC SUPREMO trial – randomised international phase III trial assessing the role of postmastectomy radiotherapy in intermediate risk breast cancer, Co-grantholders Dr P Canney, Professor A Price, Professor J Bartlett, Dr G Thomas, Professor JM Dixon, Mr R Sainsbury, Dr M Denvir, Dr E Aird, Dr T McDonagh, Dr A Bowman and Dr J Thomas. The is run under the auspices of the Breast International Group (BIG 2-04) in collaboration with Anglo-Celtic Clinical Oncology Group, European Organisation for Research and Treatment of Cancer and Australia and New Zealand Breast Cancer Trials Group. There are biological, cardiac, quality of life and health economic substudies. Target accrual is 3700 patients over 4 years with 5 years of follow up. The trial was launched in Edinburgh on 17th June 2005 and opened for accrual on 7th June 2006.

2007-2010 from RARECARE: 875,000 Euros from European Commission FP6 Programme

I was a co-grant holder for the University of Edinburgh with Dr Gemma Gatta (Chief Investigator) Cancer Epidemiologist, Istituto Tumori, Milan on a European Union Public Health programme 36 month grant proposal for €2,284,646 from 1/1/07 to (i) provide operational definition of rare cancers (ii) estimate the burden of rare cancers in Europe (iii) improve the quality of date on rare cancers (iv) develop strategies to exchange information on surveillance and treatment of rare cancers in Europe. I co-ordinate the work package on dissemination of the results for which I have received a grant of 188,019 Euros. Other work packages include Co-ordination of the project (Dr Gemma Gatta, Italy), Evaluation of the project (Professor Michel Coleman, UK), Definition and list of rare cancers (Dr Pancras Hogendoorn, The Netherlands), Health induction, Survival and Prevalence (Dr Riccardo Capoccacia, Italy) and Cancer Registry and Rare Cancers (Dr Carmen Martinez, Spain).

2007-2012: £184,839 from Cancer Research UK to cover salary and running expenses for Experimental Cancer Medicine Centre

I was co-grant holder for the Edinburgh Cancer Research Centre with Dr ARW Williams, Dr AJM Stevenson, Dr A Thomson, Dr BH Ramsahoye, Dr CD Gregory, Dr CM Abbott, Professor CMG Gourley, Professor DA Cameron, Dr D Brewster, Dr D McLaren, Dr FK Habib, Professor HAC Cubie, Professor J Bartlett, Dr J Thomas, Dr K Grigor, Dr KL Ball, Dr LA Stark, Dr L Forrester, Dr L Wall, Dr MM Wallace, Dr P Ghazal, Dr RA Goodlad, Dr RL Hayward, Dr S Guichard, Dr S Langdon, Dr SM Farrington, Dr T Riddick Dr T Sethi, Dr W Wallace, Mr AS McNeill, Professor JM Dixon, Professor AP Bird, Professor A Price, Professor DI Jodrell, Professor DJ Porteous, Professor D Melton, Professor H Campbell, Professor II Goryanin, Professor J Smyth, Professor MG Dunlop, Professor M Sharpe, Professor MT Fallon, Professor PJ Sadler, Professor R Millar, Professor R Procter, Professor SG Hillier, Professor TR Hupp.

2008: HK $1,000,000 from the William and Elizabeth Davies Foundation, Hong Kong to support the recruitment of 60 patients from a network of nine Chinese centres including Beijing and Shanghai into the MRC SUPREMO Trial.

2009-2014: 15,650,700 euros from the European Commission for Translating The Hypoxic Micro-Environment – European Commission FP7

I was the lead investigator for the University of Edinburgh in the FP7 Programme of the European Commission for a 16 million euro large scale integrating project on translating the hypoxic micro-environment in cancer submitted in September 2007. Our work assesses the anti-cancer properties of carbonic anhydrase inhibitors in vitro and in animal models and, subject to demonstration of proof of principle, in prospective clinical trials. In addition, we plan to develop ‘lab on chip’ devices to measure physiological parameters such as pH and p02 in vitro and in animal models. The project is a collaboration with Professor David Harrison, Professor John Bartlett, Dr Simon Langdon (CRUK, Edinburgh) and Professor Anthony Walton, Professor Steven McLaughlin and Professor Alan Murray, Department of Electronic Engineering, University of Edinburgh. 

2009-2016: £197,750 from the Breast Cancer Campaign – UK component of international DCIS ‘boost’ radiotherapy trial

I was Chief Investigator for a three year project grant from December 2009 from the Breast Cancer Campaign to recruit 250 patients with ductal carcinoma in situ (DCIS) after breast conserving surgery and whole breast irradiation. Patients will be randomised to a boost of 16 Gy in 8 fractions or no boost. This represents the UK component of an international trial under the auspices of the Breast International Group (BIG) which aims to recruit 2000 patients. The trial is co-funded by the EORTC and in Australia and New Zealand by NHMRC and in Canada by NCIC. Co-grantholders are: Dr P Canney (Glasgow), Mr A Thompson (Dundee), Dr Edwin Aird (Mount Vernon), Professor Fiona Gilbert (Aberdeen), Professor Sarah Pinder (London), Associate Professor Boon Chua (Melbourne), Professor Mike Dixon (Edinburgh). Ethical approval was granted in August 2010 and recruitment of 1606 patients was completed in June 2014

2010: £34,400 from the James Clerk Maxwell Cancer Research Fund

I was awarded along with Dr S Langdon, Dr C Ward and Professor D Harrison a grant by the Clerk Maxwell Cancer Research fund for a hypoxia workstation to support our experiments on combining radiotherapy and carbonic anhydrase inhibitors in the METOXIA FP7 programme.

2010-2011: £9,000 from the Breast Cancer Institute, Western General Hospital 

Salary for Dr Linda Williams, trial administrator, for follow up of patients in Prime II trial for 12 months.

2011-2016: £68,140 from the Peter Chan Jee Yet and Yeung Ying Yin and May Yeung Foundations, Hong Kong for additional follow up of 6-10 years for the 60 Chinese patients recruited to the MRC SUPREMO Trial. 

2011-2014: RARECARENet: 1,000,631 Euros from European Commission FP6 Programme. The project built an information network to provide comprehensive information on rare cancers to improve accuracy of diagnosis and identify centres of excellence in Europe and standardise practice across member states.

2013-2014: £32,753 from Lothian University Hospitals Endowment Cancer Fund

Salary for one year has been approved by LUHD Cancer fund to support the trial administrator of the DCIS ‘boost’ radiotherapy trial in Edinburgh.

2013-2019: £5.2 million programme grant as co-PI from EPSRC for IMPACT project (PI Professor Alan Murray, School of Engineering, Edinburgh University) jointly with Professor Mark Bradley (Dept. of Chemistry), Professor David Argyle (Veterinary Oncology, Roslin Institute), and Professor Steve McLaughlin, Heriot Watt University. IMPACT will develop real time 'lab on chip' biosensors of tumour hypoxia and other key biological parameters to facilitate differential radiation dose delivery to hypoxic areas of solid tumors to improve local control.

2016-2020: $658,418.75 - NHMRC Grant for BIG 3-07 DCIS boost trial to enable continuation of the BIG 3-07 clinical trial for 6 – 10 years of follow up, and commencement of the correlative translational research. Co-grantholder. CI Prof Boon Chua (University of New South Wales)

2016-2022: £46,935 from the Breast Cancer Institute Lothian Health Endowment Fund for follow up of the BIG 3.07 DCIS boost trial in the UK to support Dr Linda Williams, UK trial administrator. Principal grant holder Prof Ian Kunkler. Co-grantholders: Dr Linda Williams. Prof Mike Dixon.

2018-2020: £78,610 from Breast Cancer Now for follow up of the UK arm of the International DCIS boost trial. CI Professor Ian Kunkler. Co-applicants: Professor Galina Velikova (Leeds), Professsor Mike Dixon (Edinburgh), Dr Linda Williams (Edinburgh), Dr Catharine Dhaliwal (Edinburgh), Professor Boon Chua (Sydney)

2018-2020: £61,173.22. Breast Cancer Institute NHS Endowment fund for investigation of novel radiosensitivity predictive biomarkers in breast cancer. Co-applicant. Chief investigator Dr A Turnbull jointly with Dr M MacLennan, Dr C Martinez-Perez, Dr C Ward, Dr M Gray, Dr J Meehan, Dr S Langdon, Prof D Argyle, Prof D Cameron, Prof A Murray (Edinburgh)

October 2019-March 2020: £10,924.22. Chief Scientist's Office for Scotland for In vivo validation of novel biomarkers of response to radiotherapy in breast cancer. PIs Dr Arran Turnbull and Dr Mark Gray, Co-Investigators Dr Simon Langdon, Professor Ian Kunkler, Professor David Argyle, University of Edinburgh. 

2020-2023: $300,000 from PFS Genomics and £110,391 from Edinburgh Health Lothian Endowments to validate the Radiotype DX signature of breast cancer radiosensitivity in Scottish Conservation trial. Kunkler IH (CI), Bartlett J, Cameron DA, Jack W, Williams LJ, Loane J, University of Edinburgh, Pierce LJ, Feng FF, Speers C, PFS Genomics

2020-2024: £95,525 from NIHR Efficacy and Mechanism Programme for follow up of the MRC SUPREMO trial of postmastectomy radiotherapy in intermediate risk breast cancer. Kunkler IH (CI), Russell N, MacClennan M, Bartlett J, Velikova G, Cairns J, Anderson N, Williams LJ, Cameron DA, Chua B.

2020-2024: £47,962 from Breast Cancer Institute NHS Endowment for BIG 2-04 MRC SUPREMO trial in intermediate risk breast cancer. Professor Ian Kunkler on behalf of the SUPREMO trial management group to support SCTRU, Public Health Scotland costs for trial administration.

2020-2024: £47,962 Edinburgh Cancer Centre NHS Endowment for BIG 2-04 MRC SUPREMO trial in intermediate risk breast cancer. Professor Ian Kunkler on behalf of the SUPREMO trial management group to support SCTRU, Public Health Scotland costs for trial administration.

2022-2025: £79,002 Breast Cancer Now for BIG 3.07 DCIS boost trial phase III randomized trial. Kunkler IH, Velikova G, Williams LJ, Chua B, Dhaliwal C, Stillie A, Dixon JM

2024-27 AU$ 1.128 million

NHMRC  3 year grant, April 2024. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study, CI Prof Boon Chua (Sydney), co-CI Dr Monica Tang, Prof Tim Whelan, Dr Emma Link, Prof Geoff Delaney, Prof Ian Kunkler, Prof Penelope Schofield


2026

1.Velikova G, Russell NS, Williams LJ, Pollock R, Dixon JM, Loncaster J, Hatton M,Clarke J, Kunkler IH.Postmastectomy chest-wall irradiation for breast cancer (BIG 2-04 SUPREMO): 5 year quality-of-life results from a randomised, phase 3 trial. Lancet Oncol  in press).

2025

2.Kunkler IH, Russell NS, Anderson N, Sainsbury R, Dixon JM, Cameron D et al. for the SUPREMO trial investigators.Ten-year survival after postmastectomy chest-wall irradiation in breast cancer .N Engl J Med 2025;393:1771-83

2023

3.Kunkler IH, Williams L, Jack WJL, Cameron DA, Dixon JM (2023). Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N Engl J Med;;388(7);585-594. doi: 10.1056/NEJMoa2207586.

2022

4.Chua B, Link E, Kunkler IH et al (2022). Radiation doses and fractionation schedule in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. Aug 6;400(10350):431-440. Doi: 10.1016/S0140-6736(22)01246.

2015

5.Ian H Kunkler, Linda J Williams, Wilma J L Jack, David A Cameron, J Michael Dixon on behalf of the PRIME II investigators (2015). Breast conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology. doi.org/10.1016/S1470-2045(14)71221-5.


  1. Karlsson P, Fyles A, Chang SL, Arrick B, Baehner FL, Malmstrom P, Ferno M, Holmberg E, Sjostrom M, Liu F-F, Cameron DA, Williams LJ, Bartlett JMS, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, Jack WJ, Kunkler I, Feng FF, Speers CW, Pierce LJ, Bennett JP, Taylor KJ. Validation of a breast cancer assay for radiotherapy omission: an individual data meta-analysis. J Nat Cancer Inst 2025;117:486-495.
  2. Williams L, Kunkler IH, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA (2024). Thirty-year update of the Scottish Breast Conservation Phase III Randomised Controlled Trial of post-operative radiotherapy in women with early operable breast cancer. Lancet Oncol. Sep;25(9):1213-1221. doi: 10.1016/S1470-2045(24)00347-4. Epub 2024 Aug 7.
  3. Meattini I, Kunkler IH (2024). Omission of radiation therapy after breast conserving surgery for older women at low risk of local recurrence: One option among many. Eur J Surg Oncol. 50(4):108058. Doi:10.1016/j.esjso.2024.108058
  4. Gannon MR, Dodwell D, Miller K, Horgan K, Clements K, Medina J, Kunkler I, Cromwell DA (2022). Change in the Use of Fractionation in Radiotherapy Used for Early Breast Cancer at the Start of COVID-19 Pandemic: A Population-Based Cohort Study of Older Women in England and Wales. Clin Oncol (R Coll Radiol). May 31:S0936-6555(22)00268-0. doi: 10.1016/j.clon.2022.05.019. Online ahead of print.
  5. Farrer NJ, Higgins GS, Kunkler IH (2022). Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours. Br J Cancer.  May;126(9):1241-1243. doi: 10.1038/s41416-022-01746-1. Epub 2022 Feb 25.
  6. Kunkler I (2022). The Evolving Role of Whole Breast Hypofraction in Older Patients with Early Breast Cancer. Sem Rad Onc. 2022-04, Vol.32(2), p.155-158. doi.org/10.1016/j.semradonc.2021.11.006
  7. Jatoi I, Kunkler I (2021). Omission of sentinel node biopsy for breast cancer: historical context and future perspective on a modern controversy. Cancer. Dec 1;127(23):4376-4383. Doi: 10.1002/cncr.33960. Epub 2021 Oct 6.
  8. Dixon JM, Kunkler IH, Russell N, Thomssen C (2021). Corrigendum to “Postmastectomy radiotherapy for all node positive patients: The case against. Eur J Surg Oncol. Dec;47(12):3202. doi: 10.1016/j.ejso.2021.09.022. Epub 2021 Oct 6.
  9. Kunkler IH, Chua B (2021). Postmastectomy radiotherapy: a review. Curr Opin Oncol. 33:547-552. doi: 10.1097/CCO.0000000000000789
  10. Jatoi I, Kunkler I (2021). Omission of sentinel node biopsy for breast cancer: historical context and future perspective on a modern controversy. Cancer. Dec 1;127(23):4376-4383. Doi: 10.1002/cncr.33960. Epub 2021 Oct 6.
  11. Biganzoli L, Battisti N, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021). Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14.
  12. Dixon JM , Kunkler IH, Russell N, Thomssen C (2021). Postmastectomy    radiotherapy for all node positive patients: The case against. Eur J Surg Oncol. Oct;47(10):2515-2520. doi: 10.1016/j.ejso.2021.06.025. Epub 2021 Jun 28.
  13. Biganzoli L, Battisti N, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14.
  14. Meehan J, Gray M, Martinez-Perez C, Kay C, Willis JC, Kunkler IH, Dixon JM, Turnbull AK (2021). A novel approach for the discovery of biomarkers of radiotherapy response in breast cancer. J Pers Med. Aug 14;11(8):796. doi: 10.3390/jpm11080796.
  15. Biganzoli L, Battisti N, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021). Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14.
  16. Biganzoli L, Battisti N, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021). Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14.
  17. Dixon JM , Kunkler IH, Russell N, Thomssen C (2021). Postmastectomy radiotherapy for all node positive patients: The case against. Eur J Surg Oncol. Oct;47(10):2515-2520. doi: 10.1016/j.ejso.2021.06.025. Epub 2021 Jun 28.
  18. King MG, Link E, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH (2020). Quality of life after breast conserving therapy for non-low risk ductal carcinoma in situ: 2-year results of a randomised controlled trial (BIG 3-07/TROG 07.01). Lancet Oncology;21:685-98 doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20.
  19. King MG, Link E, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH (2020). Quality of life after breast conserving therapy for non-low risk ductal carcinoma in situ: 2-year results of a randomised controlled trial (BIG 3-07/TROG 07.01). Lancet Oncology;21:685-98 doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20.
  20. Ward C, Meehan J, Gray ME, Murray AF, Argyle DA, Kunkler IH, Langdon SP (2020). The impact of tumour pH on cancer progression: strategies for clinical intervention. Explor Target Antitumor Ther. 1:71-100. doi: 10.37349/etat.2020.00005. Epub 2020 Apr 28.
  21. Meehan J, Gray M, Martínez-Pérez C, Kay C, Pang LY, Fraser JA, Poole AV, Kunkler IH, Langdon SP, Argyle D, Turnbull AK (2020). Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Front Oncol. Apr 24;10:628. doi: 10.3389/fonc.2020.00628. eCollection 2020.
  22. Marland, J, Gray, M, Dunare, C, Blair, E, Tsiamis, A, Sullivan, P, González-Fernández, E, Greenhalgh, S,Gregson, R, Clutton, E, Parys, M, Dyson, A, Singer, M, Kunkler I, Potter, MA, Mitra, S, Terry, J, Smith, S, Mount, A, Underwood, I, Walton, A, Argyle, D & Murray, A (2020). Real-time measurement of tumour hypoxia using an implantable microfabricated oxygen sensor', Sensing and Bio-Sensing Research. Dec Vol.30 100375. doi.org/10.1016/j.sbsr.2020.100375
  23. Olivotto IA, Link E, Philips C, Whelan TJ, Bryant G, Kunkler IH, Westenberg AH, Purohit K, Ahern V, Graham PH, Akra M, McArdle O, Ludbrook JJ, Harvey JA, Maduro JH, Kirkove C, Gruber G, Martin JD, Chua BH (2019) International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiotherapy and Oncology. Jan;142:180-185. Epub 2019 Aug 17. doi.org/10.1016/j.radonc.2019.07.024.
  24. Bozdag M, Ferraroni M, Ward C, Carta F, Bua S, Angeli A, Langdon SP, Kunkler IH, Al-Tamimi AS, Supuran CT (2019). Carbonic Anhydrase inhibitors based on sorafenib scaffold: Design, sunthesis, crystallographic investigation and effects on primary breast cancer cells. Eur J Med Chem. Nov 15;182:111600. doi: 10.1016/j.ejmech.2019.111600. Epub 2019 Aug 7
  25. Gray ME, Marland JRK, Dunare C, Blair EO, Meehan J, Tsiamis A, Kunkler IH, Murray AF, Argyle D, Dyson A, Singer M, Potter MA (2019). In Vivo Validation of a Miniaturised Electrochemical Oxygen Sensor for Measuring Intestinal Oxygen Tension. Am J Physiol Gastrointest Liver Physiol. Aug 1;317(2):G242-G252. doi: 10.1152/ajpgi.00050.2019. Epub 2019 Jun 12.
  26. Velikova G, Williams L, Willis S, Dixon M, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell, N (2018). Quality of life at 2-year follow-up of SUPREMO randomised trial of post mastectomy radiotherapy for breast cancer. Quality of life after post mastectomy radiotherapy. Lancet Oncology. 19:1516-1529. doi: 10.1016/S1470-2045(18)30515-1. Epub 2018 Oct 15.
  27. Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ (2018). Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness. Metabolites. 10;8(1). pii: E13. doi: 10.3390/metabo8010013. Review
  28. Kunkler IH, Dixon JM, Maclennan M, Russell NS (2017). European interpretation of North American post mastectomy radiotherapy guideline update. Eur J Surg Oncol. Oct;43(10):1805-1807. doi: 10.1016/j.ejso.2017.04.004.
  29. Gray M, Turnbull AK, Ward C, Meehan J, Martinez-Perez C, Bonello M, Pang LY, Langdon SP, Kunkler IH, Murray A, Argyle D (2019). Development and characterisation of acquired radioresistant breast cancer cells. Radiat Oncol. April 15;14(1):64. doi:10.1186/s13014-019-1268-2
  30. Gray M, Meehan J, Blair EO, Ward C, Langdon SP, Morrison LR, Marland JRK, Tsiamis A, Kunkler IH, Murray A, Argyle D (2018). Biocompatibility of Common Implantable Sensor Materials in a Tumor Xenograft Model. Journal of Biomedical Research Part B: Applied Biomaterials. Oct 27. doi:10.1002/jbm.6.34254.
  31. Ikegwuonu, T., Haddow, G., Tait, J., Murray, A. F. & Kunkler, I. H (2018). Horizon scanning implanted biosensors in personalising breast cancer management: First pilot study of breast cancer patients views. Health Science Reports. 15 Mar, e30, pp. 1-9. doi: 10.1002/hsr2.30.
  32. Jatoi I, Benson JR, Kunkler I (2018). Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy in breast cancer. NPJ Breast Cancer. Apr 3;4:8. doi: 10.1038/s41523-018-0061-y
  33. Gray M, Meehan J, Ward C, Langdon S P, Kunkler I H, Murray A., Argyle D (2018). Implantable biosensors and their contribution to the future of precision medicine. The Veterinary Journal. Sep;239:21-29. doi: 10.1016/j.tvjl.2018.07.011. Epub 2018 Jul 29.
  34. Jeremy Thomas, Andrew Hanby, Nicola Russell, Geertjen van Tienhove, Kathleen Riddle, Niall Anderson, David Cameron, John Bartlet, Angela Bowman, Tammy Piper, Carrie Cunningham, Peter Canney, Ian Kunkler (2017). On behalf of the SUPREMO Trial Management Group. The BIG 2.04 MRC/EORTC SUPREMO Trial – Pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Research and Treatment. Feb 11. doi: 10.1007/s10549-017-4145-4.
  35. Kunkler IH, Dixon JM, Maclennan M, Russell NS (2017). European interpretation of North American post mastectomy radiotherapy guideline update. Eur J SurgOncol. Oct;43(10):1805-1807. doi: 10.1016/j.ejso.2017.04.004.
  36. Meehan J, Ward C, Turnbull A, Bukowski- Wills J, Finch AJ, Jarman EJ, Xintaropoulou C, Martinez-Perez C,Gray M, Pearson M, Mullen P, Supuran CT,Carta F, Harrison DJ, Kunkler IH (2017). Langdon SP. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget. Jun 27;8(26):42857-42875. doi: 10.18632/oncotarget.17143.
  37. Mislang AR, Cheung KL, Hamaker ME, Kunkler I, Markopoulos C, Orecchia R, Brain E, Biganzoli L (2017). Controversial issues in the management of older adults with early breast cancer. J Geriatr Oncol. Nov;8(6):397-402. doi: 10.1016/j.jgo.2017.05.004. Epub 2017 Jun 9.
  38. Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JM, Ellis IO (2016). Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. J Pathol Clin Res. 15:32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.
  39. Dixon JM, Newlands C, Dodds C, Thomas J, Williams LJ, Kunkler IH, Bing A, Macaskill EJ (2016). Association between underestimation of tumour size by imaging and incomplete excision in breast-conserving surgery for breast cancer. Br J Surg. Jun;103(7):830-8. doi: 10.1002/bjs.10126.
  40. Ian H Kunkler, Linda J Williams, Wilma J L Jack, David A Cameron, J Michael Dixon on behalf of the PRIME II investigators (2015). Breast conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology. doi.org/10.1016/S1470-2045(14)71221-5.
  41. Haddow G, King E, Kunkler I, McLaren D (2015). Cyborgs in the Everyday: Masculinity and Biosensing Prostate Cancer. Sci Cult (Lond). Oct 2;24(4):484-506. doi: 10.1080/09505431.2015.1063597. Epub 2015 Sep 3.
  42. Kunkler IH, Ward C, Langdon SP (2015). Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow. Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow. Breast. Sep 28. pii: S0960-9776(15)00164-2. doi: 10.1016/j.breast.2015.07.026. [Epub ahead of print].
  43. Carol Ward, James Meehan, Peter Mullen, Claudiu Supuran, J. Michael Dixon, Jeremy S. Thomas, Jean-Yves Winum, Philippe Lambin, Ludwig Dubois, Nanda-Kumar Pavathaneni, Edward J. Jarman, Lorna Renshaw, InHwa Um, Charlene Kay, David J. Harrison, Ian H. Kunkler, Simon P. Langdon (2015). Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. Sep 22;6(28):24856-70. doi: 10.18632/oncotarget.4498.
  44. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS (2015). Personalization of loco-regional care for primary breast cancer patients (part 2).Kyoto Breast Cancer Consensus Conference. Future Oncol. 11(9):1301-5. doi: 10.2217/fon.15.66.
  45. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS (2015). Personalization of loco-regional care for primary breast cancer patients (part 1). Kyoto Breast Cancer Consensus Conference. Future Oncol. 11(9):1297-300. doi: 10.2217/fon.15.65.
  46. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T (2015). FKBPL: a marker of good prognosis in breast cancer. Oncotarget. May 20;6(14):12209-23. doi: 10.18632/oncotarget.3528.
  47. Y Belkacemi, O Kaidar-Person, P Poortmans, M Ozsahin, M-C Valli, N Russell, I Kunkler, J Hermans, A Kuten, G van Tienhoven, H Westenberg on behalf of the Breast Working Party of the EORTC Radiation Oncology Group (ROG) (2015). Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) Nodal Radiotherapy (NORA) survey. Annals of Oncology. 00:1-7. doi:10.1093/annonc/mdu561.
  48. Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange J-L, Markouizou A, Pfeffer R, Villa S – On behalf of the SIOG Radiotherapy Task Force (2014). Review of current best practice and priorities for research in radiation therapy for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Annals of Oncology. 25(11):2134-2146. doi: 10.1093/annonc/mdu104. Epub 2014 Mar 13.
  49. Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange J-L, Markouizou A, Pfeffer R, Villa S – On behalf of the SIOG Radiotherapy Task Force (2014). Review of current best practice and priorities for research in radiation therapy for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Annals of Oncology. 25(11):2134-2146. doi: 10.1093/annonc/mdu104. Epub 2014 Mar 13.
  50. C Ward, SP Langdon, P Mullen, AL Harris, DJ Harrison, IH Kunkler (2013). New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treatment Reviews. 39:171-179. doi: 10.1016/j.ctrv.2012.08.004.
  51. Biganzoli L , Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd A, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncology. 13;4:e148-e160. doi: 10.1016/S1470-2045(11)70383-7. Epub 2012 Mar 30.
  52. Winum J-Y, Carta F, Ward C, Mullen P, Harrison D, Langdon SP, Cecchi A, Scozzafava A, Kunkler I, Supuran CT (2012). Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters. 22;14:4681-4685. doi: 10.1016/j.bmcl.2012.05.083.
  53. Melanie Spears, Carrie A. Cunningham, Karen J. Taylor, Elizabeth A Mallon, Jeremy St. J Thomas, Gillian R Kerr, Wilma JL Jack, Ian H Kunkler, David A Cameron, Udi Chetty, John MS Bartlett (2012). Proximity ligation assays for isoform specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology. 227:481-489. doi: 10.1002/path.4022. Epub 2012 Apr 30.
  54. Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JStJ, Kerr GR, Jack WJL, Kunkler IH, Cameron DA, Chetty U, Bartlett JMS (2012). The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Research Treatment. 131;2:463-472. doi: 10.1007/s10549-011-1426-1. Epub 2011 Mar 9.
  55. Kunkler IH, Kerr GR, Thomas JS, Jack WJL, Bartlett JMS, Pedersen HC, Cameron DA, Dixon JM, Chetty U (2012). Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long term follow up. International Journal of Radiation Oncology, Biology, Physics. 83:829-838. doi: 10.1016/j.ijrobp.2011.08.018. Epub 2011 Dec 22.
  56. Munshi A, Prabhu A, Kunkler I (2012). Post mastectomy radiotherapy in one to three lymph node positive breast cancer. Acta Oncologica. 51;4:547-550. doi: 10.3109/0284186X.2011.633929. Epub 2011 Dec 1.
  57. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licintra L, Mallone S, Tavilla A, Trama A, Capocaccia R and the RARECARE Working Group (2011). Rare cancers are not so rare: the rare cancer burden in Europe. European Journal of Cancer. 47;17:2493-2511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25.
  58. Mary Anne Quintayo, Alison F Munro, Jeremy Thomas, Ian H Kunkler, Wilma Jack, Gillian R Kerr, JM Dixon, Udi Chetty, John MS Bartlett (2012). GSK3b and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Research Treatment. 136:161-168. doi: 10.1007/s10549-012-2229-8. Epub 2012 Sep 14.
  59. Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL, Smith IE (2012). UK Guidance Document: Treatment of Metastatic Breast Cancer. Clinical Oncology. 24:169-176. doi: 10.1016/j.clon.2011.10.004. Epub 2011 Nov 8.
  60. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licintra L, Mallone S, Tavilla A, Trama A, Capocaccia R and the RARECARE Working Group (2011). Rare cancers are not so rare: the rare cancer burden in Europe. European Journal of Cancer. 47;17:2493-2511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25.
  61. Ring A, Reed M, Leonard R, Kunkler I, Muss H, Wildiers H, Fallowfield L, Jones A, Coleman R (2011). The treatment of early breast cancer in women over the age of 70. British Journal of Cancer. 105;2:189-193. doi: 10.1038/bjc.2011.234. Epub 2011 Jun 21.
  62. LJ Williams, IH Kunkler, CC King, W Jack, M van der Pol (2011). A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of Life at five years in the PRIME trial. Health Technology Assess. Mar;15(12):i-xi, 1-57. doi: 10.3310/hta15120.
  63. Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH (2011). Breast radiotherapy for Occult Breast Cancer with Axillary Nodal Metastases – Does it Reduce the Local Recurrence Rate and Increase Overall Survival. Clinical Oncology. 23;2:95-100. doi: 10.1016/j.clon.2010.10.001. Epub 2010 Nov5.
  64. Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U (2010). Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Research. 12;4:R47. doi: 10.1186/bcr2604. Epub 2010 Jul 8.
  65. Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, Baili P; EUROCHIP Working Group Collaborators: Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D, Comber H, Micheli A, Baili P, Amati C, Casella I, Cifalà A, Esposito M, Saltarelli S, Di Salvo F, Ciampichini R, Berrino F, Gatta G, Sant M, Ciccolallo L, Allemani C, Capocaccia R, Verdecchia A, Merzagora F, Costa A, Viberga I, Engele L, Kurtinaitis J, Kurtinaitiene R, Couffignal S, Dalmas M, Busuttil R, Bielska Lasota M, Miranda A, Apostol I, Baban A, Plesko I, Ondrusova M, Zakeli M, Zadnik V, Martinez C, Navarro C, Lutz JM, Quinto C, Otter R, Schaapveld M, Coleman M, Kunkler I, Gavin A, Bannon F (2010). Cervical cancer assessment in Romania under EUROCHIP-2. Tumori. 96;4:545-552. doi: 10.1177/030089161009600406.
  66. Valerianova Z, Panayotova Y, Amati C, Baili P; EUROCHIP Working Group Collaborators: Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Vasiliev N, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D, Comber H, Micheli A, Baili P, Amati C, Casella I, Cifalà A, Esposito M, Saltarelli S, Di Salvo F, Ciampichini R, Berrino F, Gatta G, Sant M, Ciccolallo L, Allemani C, Capocaccia R, Verdecchia A, Merzagora F, Costa A, Viberga I, Engele L, Kurtinaitis J, Kurtinaitiene R, Couffignal S, Dalmas M, Busuttil R, Bielska Lasota M, Miranda A, Apostol I, Baban A, Plesko I, Ondrusova M, Zakeli M, Zadnik V, Martinez C, Navarro C, Lutz JM, Quinto C, Otter R, Schaapveld M, Coleman M, Kunkler I, Gavin A, Bannon F (2010). Cervical cancer screening in Bulgaria – past and present experience. Tumori. 96; 4:538-544. doi: 10.1177/030089161009600405.
  67. Viberga I, Engele L, Baili P; EUROCHIP Working Group Collaborators: Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D, Comber H, Micheli A, Baili P, Amati C, Casella I, Cifalà A, Esposito M, Saltarelli S, Di Salvo F, Ciampichini R, Berrino F, Gatta G, Sant M, Ciccolallo L, Allemani C, Capocaccia R, Verdecchia A, Merzagora F, Costa A, Viberga I, Engele L, Kurtinaitis J, Kurtinaitiene R, Couffignal S, Dalmas M, Busuttil R, Bielska Lasota M, Miranda A, Apostol I, Baban A, Plesko I, Ondrusova M, Zakeli M, Zadnik V, Martinez C, Navarro C, Lutz JM, Quinto C, Otter R, Schaapveld M, Coleman M, Kunkler I, Gavin A, Bannon F (2010). Past, present and future of the cervical cancer screening in Latvia. Tumori. 96;4:529-537. doi: 10.1177/030089161009600404.
  68. Veerus P, Arbyn M, Amati C, Paolo B; EUROCHIP Working Group Collaborators: Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D, Comber H, Micheli A, Baili P, Amati C, Casella I, Cifalà A, Esposito M, Saltarelli S, Di Salvo F, Ciampichini R, Berrino F, Gatta G, Sant M, Ciccolallo L, Allemani C, Capocaccia R, Verdecchia A, Merzagora F, Costa A, Viberga I, Engele L, Kurtinaitis J, Kurtinaitiene R, Couffignal S, Dalmas M, Busuttil R, Bielska Lasota M, Miranda A, Apostol I, Baban A, Plesko I, Ondrusova M, Zakeli M, Zadnik V, Martinez C, Navarro C, Lutz JM, Quinto C, Otter R, Schaapveld M, Coleman M, Kunkler I, Gavin A, Bannon F (2010). Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori. 96;4:524-528. doi: 10.1177/030089161009600403.
  69. Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group Collaborators: Hackl M, Zielonk N, Van Eycken E, Henau K, Schrijvers D, Sundseth H, Geissler J, Blaes P, Marreaude S, Audisio R, Znaor A, Mägi M, Hedelin G, Velten M, Launoy G, Guizard AV, Fairvre J, Bouvier AM, Maynadiá M, Manivet I, Mercier M, Buemi A, Tretarre B, Colonna M, Molinié F, Lacour B, Bara S, Schvart C, Ganry O, Grosclaude P, Benhamou E, Grossgoupil M, Coquard IR, Droz JP, Baconnier S, Holleczek B, Wartenberg M, Hehlmann R, Tryggvadottir L, Comber H, Deady S, Bellù F, Ferretti S, Serraino D, Vercelli M, Quaglia A, Vitarelli S, Federico M, Cirilli C, Fusco M, Traina A, Michiara M, Bozzani F, Giacomin A, Tumino R, Cilia S, Spata E, Mangone L, Falcini F, Foca F, Senatore G, Iannelli A, Budroni M, Piffer S, Franchini S, Crocetti E, Caldarella A, La Rosa F, Stracci F, Contiero P, Tagliabue G, Zambon P, Fiore A, Berrino F, Casali PG, Gatta G, Gronchi A, Licitra L, Olmi P, Ruzza M, Sowe S, Trama A, Capocaccia R, De Angelis R, Mallone S, Tavilla A, Dei Tos AP, Fleming J, Brandes AA, England K, Langmark F, Bray F, Rachtan J, Gozdz S, Mezyk R, Zwierko M, Bielska-Lasota M, Slowinski J, Miranda A, Primic-zakelj M, Ondrusova M, Mateos A, Izarzugaza I, Martínez R, Marcos-Gragera R, Sánchez MJ, Navarro C, Chirlaque MD, Ardanaz E, Mareno C, Galceran J, Virizuela-Echaburu JA, Gonzalez-Campora R, Martínez-García C, Melchor JM, Cervantes A, Adolfsson J, Lambe M, Möller TR, Ringborg U, Jundt G, Usel M, Frick H, Ess SM, Bordoni A, Luthi JC, Dehler S, Lutz JM, Visser O, Otter R, Siesling S, van der Zwan JM, Coeberg JW, Sollie A, Schouten H, Greenberg DC, Forman D, Roche M, Verne J, Meechan D, Lawrence G, Coleman MP, Mackay J, Gavin A, Brewster DH, Black RJ, Kunkler I, Steward J, White C (2010). The burden of rare cancers in Europe. Adv Exp Med Biol. 686: 285-303. doi: 10.1007/978-90-481-9485-8_17.
  70. Kunkler I (2010). Adjuvant chest wall radiotherapy for breast cancer: Black, white and shades of grey. European Journal of Surgical Oncology. 36:331-334. doi: 10.1016/j.ejso.2009.11.004. Epub 2009 Nov 24.
  71. Thomas J St J, Kerr GR, Jack WJL, Campbell F, McKay L, Pedersen HC, Kunkler IH, Cameron DA, Chetty U, Bartlett JMS (2009). Histological grading of invasive breast carcinoma - a simplification of existing methods in a large conservation series with long-term follow up. Histopathology. 54:724-731. doi: 10.1111/j.1365-2559.2009.03429.x.
  72. Kunkler IH (2009). Radiotherapy of the regional lymph nodes: shooting at the sheriff? The Breast. 18;S3:S112-S120. doi: 10.1016/S0960-9776(09)70285-1.
  73. AB Law, T Evans, RL Hayward, GS Higgins, KL Murray, D Summers, IKunkler (2009). Possible Radiation Sensitisation by Trastuzumab Leading to Radiation Induced Myelitis. Breast Care. 4;1:40-42. doi: 10.1159/000193069. Epub 2009 Feb 20.
  74. Kunkler IH, Williams LJ, King CC, Jack W (2009). Breast radiotherapy: considerations in older patients. Clinical Oncology Special Edition. 21:111-117. doi: 10.1016/j.clon.2008.11.012. Epub 2009 Jan 4.
  75. J Cameron, M Smith, I Kunkler (2008). Ultrasound breast boosts: A pilot study. Radiography. 14:135-137. doi: 10.1016/j.radi.2006.09.003
  76. Verdecchia A, Baili P, Quaglia A, Kunkler I, Ciampichini R, Berrino F, Micheli A (2008). Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health. 18: 527-532. doi: 10.1093/eurpub/ckn022. Epub 2008 Apr 15.
  77. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M, Giordano SH, Muss H, Aapro M (2007). Management of Breast Cancer in the Elderly: Recommendations of the International Society of Geriatric Oncology (SIOG). Lancet Oncology. 8:1101-1115. doi: 10.1016/S1470-2045(07)70378-9.
  78. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M, Giordano SH, Muss H, Aapro M (2007). Management of Breast Cancer in the Elderly: Recommendations of the International Society of Geriatric Oncology (SIOG). Lancet Oncology. 8:1101-1115. doi: 10.1016/S1470-2045(07)70378-9.
  79. Montgomery DA, Krupa K, Jack WJL, Kerr GR, Kunkler IH, Thomas J, Dixon JM (2007). Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. British Journal of Cancer. 96:1802-1807. doi: 10.1038/sj.bjc.6603815. Epub 2007 May 29.
  80. Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, Bowman A, Neades G, Walls ADF, Chetty U, Dixon JM, Smith ME, Gardner TW, Macnab M, Swann S, Maclean JR (2007). TELEMAM: a cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making. European Journal of Cancer. 43;17:2506-2514. doi: 10.1016/j.ejca.2007.08.026. Epub 2007 Oct 24.
  81. Prescott RJ, Kunkler IH, Williams LJ, King CC, Jack W, Van der Pol M, Goh TT, Lindley R, Cairns J (2007). PRIME I: assessing the impact of adjuvant breast radiotherapy on quality of life in low risk older patients following breast conserving surgery. Health Technology Assessment. 11:1-49. doi: 10.3310/hta11310.
  82. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I and the EUROCARE-4 Working Group (2007). Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncology. 8:784-796. doi: 10.1016/S1470-2045(07)70246-2.
  83. Prescott RJ, Kunkler IH, Williams LJ, King CC, Jack W, Van der Pol M, Goh TT, Lindley R, Cairns J (2007). PRIME I: assessing the impact of adjuvant breast radiotherapy on quality of life in low risk older patients following breast conserving surgery. Health Technology Assessment. 11:1-49. doi: 10.3310/hta11310.
  84. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman M, De Angelis R, Faivre J, Lutz JM, Martinez C, Moller T, Sankila R and the EUROCARE Working Group (2006). Survival for rare cancers. Lancet Oncology. 7:132-140. doi: 10.1016/S1470-2045(05)70471-X.
  85. Kunkler IH, Fielding RG, Macnab M, Swann S, Brebner JA, Prescott RJ, Maclean RJ, Chetty U, Bowman, A, Neades G, Dixon JM, Smith ME, Walls ADF, Cairns J, Lee RJ, Lee AJ, Gardner T. (2006). Group dynamics within telemedicine and standard multidisciplinary team meetings: results from the TELEMAM randomised trial. J  Telemed Telecare. 12:S3:55-58. doi.org/10.1258/135763306779380156
  86. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman M, De Angelis R, Faivre J, Lutz JM, Martinez C, Moller T, Sankila R and the EUROCARE Working Group (2006). Survival for rare cancers. Lancet Oncology. 7:132-140. doi: 10.1016/S1470-2045(05)70471-X.
  87. Steele N, Zekri J, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O Coleman R, Cameron D (2006). Exemestane in metastatic breast cancer: effective therapy after 3rd generation non-steroidal aromatase inhibitor failure. The Breast. Jun;15(3):430-6. doi: 10.1016/j.breast.2005.08.032. Epub 2005 Oct 19.
  88. Kunkler IH, Prescott RJ, Williams L J, King CC (2006). When may adjuvant radiotherapy be avoided in operable breast cancer? Clinical Oncology. Apr;18(3):191-9. doi: 10.1016/j.clon.2005.11.005.
  89. Fielding RG, Macnab M, Swann S, Kunkler IH, Brebner J, Prescott R, Maclean JR, Chetty U, Neades G, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, Lee M, Lee R (2005). Attitudes of stakeholders to standard and telemedicine delivered multidisciplinary meeting. J Telemed and Telecare.(Attitudes of breast cancer professionals to conventional and telemedicine-delivered multidisciplinary breast meetings) 11;Suppl 2:S29-34. doi.org/10.1258/135763305775124812
  90. ai P, Yu E, Cserni G, Vlastos G, Royce M, Kunkler I, Vinh-Hung V (2005). Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database. BMC Cancer. 5:48. doi: 10.1186/1471-2407-5-48.
  91. Kunkler IH, Fielding RG, Brebner J, Prescott R, Maclean R, Cairns J, Chetty U, Neades G, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, MacCoubrey J, Lee A J, Swann S, Macnab M, Wilson J, Nawroz I (2005). A comprehensive approach for evaluating telemedicine delivered multidisciplinary breast cancer meetings in Southern Scotland. J Telemed Telecare. 11; Suppl 1:71-73. doi.org/10.1258/1357633054461804.
  92. Kunkler IH (2004). Cure, palliation, and cost in cancer care. Lancet Oncology. Dec;5(12):709. doi: 10.1016/S1470-2045(04)01644-4.
  93. Kunkler IH, James N, Maher J (2004). Radiotherapy in 2025. Expert Rev Anticancer Ther. Jun;4 Suppl 1:S37-41. doi: 10.1586/14737140.4.5.s37.
  94. Davison AM and Kunkler IH (2004). Medical postgraduate training and practice in the expanded European Union. J Roy Coll Phys Edinb. 34(2):120-123.
  95. Meyers CA, Smith JA, Bezjak A, Liebmann J, Illidge T, Kunkler I, Caudrelier J-M, Eisenberg PD, Meerwaldt J, Ross S, Carrie C, Gaspar L, Curran W, Mehta MP, See-Chun P, Miller RA, Renschler MF (2004). Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium (MGd): Results of a randomised phase 111 trial. J Clin Oncol. 22:157-165. doi: 10.1200/JCO.2004.05.128.
  96. Levack P, Graham J, Kidd J, Collie D, Grant R, Kunkler IH et al (2002). Listen to the symptoms: don’t wait for the sensory level. The Scottish Spinal Cord Compression Group. Clin Oncol. 14:472-480. doi.org/10.1053/clon.2002.0098.
  97. Kunkler IH, King CC, Williams LJ, Prescott RJ, Jack W (2001). What is the evidence for a reduced risk of local recurrence with age among older patients treated by breast conserving therapy? The Breast. 10:464-469. doi.org/10.1054/brst.2001.0300.
  98. Kunkler IH (2000). Managed clinical networks: a new paradigm for clinical medicine. J Roy Coll Physicians Lond. 34:230-233. PMID: 10904913.
  99. Young IE, Kurian KM, Mackenzie MA, Kunkler IH, Cohen BB, Hooper ML, Wyllie A (2000). A polymorphic tetranucleotide repeat in the CYP19 gene and male breast cancer. Br J Cancer. 82:1247-1248. doi: 10.1054/bjoc.1999.1085.
  100. Young IE, Kurian KM, Mackenzie MA, Kunkler IH, Cohen BB, Hooper ML, Wyllie A (2000). The CAG repeat within the androgen receptor gene in male breast cancer. J Med Genet. 37:139-140. doi: 10.1136/jmg.37.2.139.
  101. Collie DA, Brush JP, Lammie G A, Grant R, Kunkler IH, Leonard R, Gregor A, Sellar R (1999). Imaging features of leptomeningeal metastases. Clin Oncol. 54:765-771. doi: 10.1016/s0009-9260(99)91181-9.
  102. Kunkler IH (1999). Lessons from a symposium on breast cancer. Proc R Coll Physicians Edinb. 29:116-119.
  103. Young IE, Kurian KM, Annink C, Kunkler IH, Steel CM, Cohen BB, Hooper M. (1999). A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer. 81(1):141-143. doi: 10.1038/sj.bjc.6690663.
  104. Brown L J., Redpath AT and Kunkler IH (1999). The use of compensators to optimise the 3-dimensional dose distribution in radiotherapy of the intact breast. Radiother Oncol. 50(3):291-300. Doi.10.1016/s0167-8140(98)00141-8 (First author Carruthers LJ)
  105. Carruthers L J, Redpath A T, Kunkler I H (1998) [Jack W, Kerr GR and Kunkler IH (1998)]. Long-term follow up after breast conservation: the Edinburgh experience. The Breast. 7(2):80-84. doi.org/10.1016/S0960-9776(98)90061-3.
  106. Kerr GR, Kunkler IH, Langlands AO, Rodger A (1998). (In) curability of breast cancer: a 30 year report of a series of 3393 cases. The Breast. 7:90-94. https://doi.org/10.1016/S0960-9776(98)90063-7.
  107. Nickers P, Scalliet P and Kunkler IH (1998). Modern brachytherapy: current state and future prospects. Eur J Cancer. 33(11):1747-1751. doi: 10.1016/s0959-8049(97)00300-6.
  108. Kunkler IH, Rafferty P, Henry M, Hill D, Foreman D (1998). Tele-oncology in Scotland: a pilot study. J Telemed Telecare. 4(2):113-119. doi: 10.1258/1357633981932055.
  109. Samuel LM, Kunkler I, Dixon M, Walker W S (1997). Pleurocutaneous fistula as a complication of radiation treatment in locally advanced breast cancer. J Roy Coll Surg Edinb. 42(2):138-139. PMID: 9114690
  110. Rennie I, Forster D, Kemeny A, Walton L, Kunkler I (1996). The use of single fraction Leksell stereotactic radiosurgery in the treatment of uveal melanoma. Act Opth Scand. 74(6):558-562. doi: 10.1111/j.1600-0420.1996.tb00734.x.
  111. Cameron DA, Craig J, Gabra H, Lee L, MacKay J, Parker AC, Leonard RC, Anderson E, Anderson T, Chetty U, Dixon M, Hawkins A, Jack W, Kunkler I, Leonard R, Matheson L, Miller W (1996). High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer – phase I/II study. Edinburgh Breast Group. British Journal of Cancer. 74(12):2013-2017. doi: 10.1038/bjc.1996.669.
  112. Daly MM and Kunkler IH (1995). Chylothorax in non-Hodgkin lymphoma managed by mediastinal radiotherapy. Clin Oncol. 7(6):397-399. doi: 10.1016/s0936-6555(05)80015-9.
  113. Makris A and Kunkler IH (1995). Controversies in the management of malignant spinal cord compression. Clin Oncol. 7(2):77-81. doi: 10.1016/s0936-6555(05)80805-2.
  114. Makris A and Kunkler IH (1995). The Barthel Index in assessing the response to palliative radiotherapy in malignant spinal cord compression. A prospective audit. Clin Oncol. 7(2):82-86. doi: 10.1016/s0936-6555(05)80806-4.
  115. Chaussagne D, Sismndi P, Horiot JC, Sinistrero G, Bey P, Zola P, Pernot M, Gerbaulet A, Kunkler I, Michel G (1993) Radiother Oncol Mar;26(3):195-202. doi: 10.1016/0167-8140(93)90260-f.
  116. Chassagne D, Kunkler IH, Horiot JC, Sinistrero G, Zola P, Pernot M, Gerbaulet A (1993). A glossary of complications of gynaecological radiotherapy. Radiother Oncol. 26:195-203.
  117. Forster DM, Kunkler IH and Hartland P (1993). Risk of cerebral bleeding from arterio-venous malformations in pregnancy: the Sheffield experience. Stereotact. Funct. Neurosurg. 61: Suppl. 1:20-22. doi: 10.1159/000100655.
  118. Radstone CR, Kunkler IH, Hancock BW, Symon G and Fitter M (1992). Organise, analyse and computerise. British Journal of Healthcare Computing. 9:21-24.
  119. Symon G, Fitter M, Kunkler IH, Radstone CR and Hancock BW (1992). The process of deriving requirements for a hospital information system. Behaviour and Information Technology. 131-140.
  120. Franklin C and Kunkler IH (1992). Carcinoma of the male breast metastatic to the mandible. Clinical Oncology. 4(1):62-63. doi: 10.1016/s0936-6555(05)80782-4.
  121. Laing R, Jakubowski J, Kunkler IH, Hancock BW (1992). Primary spinal presentation of non-Hodgkin’s lymphoma. A reappraisal of management and prognosis (Non-Hodgkin lymphoma presenting with spinal extradural compression: report of 13 cases and a review of the literature). Spine. 17(1):117-120. doi: 10.1097/00007632-199201000-00019
  122. Gerbaulet A, Kunkler IH, Kerr G R, Haie C, Michel G, Dutreix A and Chassagne D (1992). Results and complications of combined low dose brachytherapy and surgery in early carcinoma of the cervix. Radiother Oncol. 2:66-73. doi: 10.1016/0167-8140(92)90337-t.
  123. Lusinchi A, Dube P, Kunkler IH, Luboinski B, Eschwege F (1989). Radiation therapy in the treatment of early glottic carcinoma: the experience of Villejuif. Radiother Oncol. 15(4): 313-319. doi: 10.1016/0167-8140(89)90076-5.
  124. Lusinchi A, Wibault P, Marandas P, Kunkler IH, Eschwege F (1989). Exclusive radiation therapy in the treatment of early tonsillar tumours. Int J Rad Oncol Biol Phys. 17(2):273-277. doi: 10.1016/0360-3016(89)90439-2.
  125. Kunkler IH, Ludgate SM, Kerr GR (1989). The value of follow up in FIGO stage 1 carcinoma of the cervix. Clin Radiol. 40(3):299-301. doi: 10.1016/s0009-9260(89)80213-2.
  126. Thomas F, Arriagada R, Mauresse H, Sillet-Bach I, Kunkler IH, Fontaine F, Le Chevalier T, Contesso, G, Sarrazin D (1988). Radical radiotherapy alone in inoperable breast cancer: the impact of tumour size and histological grade on prognosis. Radiother Oncol. 13(4):267-276. doi: 10.1016/0167-8140(88)90222-8
  127. Nickers P, Oosters L, Brasseur F, Kunkler IH, Maisin H, Deckers C (1988). Correlation between size and external temperature in 4 rat tumours after treatment with cytostatic agents. J Cancer Res Clin Oncol. 114(1):81-86. doi: 10.1007/BF00390489.
  128. Kunkler IH (1987). Unsuspected extent of irradiation for ringworm of the scalp in childhood. J Roy Coll Surg Edinb. 32(2):105-106.
  129. Kunkler IH and Merrick MV (1986). The value of non-staging skeletal scintigraphy in breast cancer. Clin Radiol. 37(6):561-562. doi: 10.1016/s0009-9260(86)80020-4.
  130. Kunkler IH, Merrick MV and Rodger A (1985). Bone scintigraphy in breast cancer. A 9 year follow up. Clin Radiol. 36(3):279-282. doi: 10.1016/s0009-9260(85)80060-x.
  131. Kunkler IH and Cookson JB (1984). Chest wall venular dilatation: a sign of chronic bronchitis. BMJ. 289(6460):1744. doi: 10.1136/bmj.289.6460.1744-a.

  1. Kunkler IH, Russell NS, Anderson N, Sainsbury R, Dixon JM, Cameron DA. In response to ASTRO response to BIG 2.04 MRC/EORTC SUPREMO trial. Int J Rad Oncol Biol 2026;125:662.
  2. Russell NS, Dixon JM, Sainsbury R, Chua B, Thomas JS,Hanby AM,Kunkler IH. In response to Machiels et al. Reconsidering the role of PMRT in low to intermediate risk breast cancer: applying results from previous standards of treatments in the current multimodal practice. Radiother Oncol (in press)
  3. Kunkler IH. Concerns about the role of physician associates in UK clinical practice. Lancet. 2025 Dec 21;404(10471):2541. doi: 10.1016/S0140-6736(24)02607-2.
  4. Ian Kunkler, David Cameron, Mike Dixon, Linda Williams (2024). Adjuvant radiotherapy omission in early breast cancer the PROSPECT Trial. The Lancet. 2024 Aug 10;404(10452):525. doi: 10.1016/S0140-6736(24)01361-8.
  5. Ian Kunkler (2024). Improving future UK pandemic management structure, Lancet. 15;403(10444):2592. doi: 10.1016/S0140-6736(24)01007-9.
  6. Chua B, Link E, Kunkler IH et al (2023). Radiation doses and fractionation schedule in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – Authors’ reply. Lancet. 401(10370):24. doi: 10.1016/S0140-6736(22)02373-X.
  7. Kunkler IH (2017). Genome-based model for adjusted radiotherapy dose: a step too far? Lancet Oncology. 18:e128. https://doi.org/10.1016/S1470-2045(17)30090-6
  8. Kunkler Ian H (2014). The need for preclinical studies of combined modality systemic therapy plus radiotherapy. BMJ. 349:g5649. (Published 17 September 2014) https://doi.org/10.1136/bmj.g5649
  9. Kunkler Ian H (2012). Randomised controlled trials of proton beam therapy are needed. BMJ. May 8;344:e3193. doi: 10.1136/bmj.e3193.
  10. Kunkler I (2012). What price cure? Lancet Oncology. 13;1:e2. https://doi.org/10.1016/S1470-2045(11)70418-1
  11. Cameron D, Kunkler I, Dixon M, Jack W, Thomas J, Kerr GR (2010). Correspondence re TARGIT-A trial – not yet ready for Prime time? Lancet. 376;9735:91-102.
  12. Russell NS, Kunkler IH, Tienhoven G van, Canney PA, Thomas J, Bartlett J, Vijver MJ van de, Belkacemi Y, Yarnold JR, Barrett-Lee PJ (2009). Post Mastectomy Radiotherapy: will SUPREMO end the debate? Journal of Clinical Oncology. 20;27(6):996-7; author reply 997-8. doi: 10.1200/JCO.2008.18.7062. Epub 2009 Jan 21.
  13. Kunkler IH (2006). Is a radiotherapy boost truly beneficial? Lancet Oncology. 10:795-796. doi: 10.1016/S1470-2045(06)70877-4.
  14. Kunkler I (2006). Recipe for NHS reform. Lancet. 368:645. 19;368(9536):645. doi: 10.1016/S0140-6736(06)69242-8
  15. Kunkler I (2006). Dose and fractionation regimens for breast cancer. Lancet Oncology. 8:617-619. doi: 10.1016/S1470-2045(06)70773-2
  16. Kunkler I (2006). Re: Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Institute. 98(14):1020-1021.
  17. Kunkler I (2006). Is it time for a National Cancer Act in the UK? Lancet Oncology. 6:452-453. doi: 0.1016/S1470-2045(06)70707-0
  18. Kunkler I (2006). Effects of radiotherapy and surgery for early breast cancer. Lancet. 20;367(9523):1653-4; author reply 1654-5. doi: 10.1016/S0140-6736(06)68725-4.
  19. Kunkler I (2006). Surgical resection in metastatic spinal cord compression. Lancet. 14;367(9505):109; author reply 109-10. doi: 10.1016/S0140-6736(06)67955-5.
  20. Kunkler IH (2005). Time for Ofhealth. BMJ. 22;331(7522):965. doi: 10.1136/bmj.331.7522.965.
  21. Kunkler IH (2005). Re: Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20 year results of the British Columbia randomised trial. J Nat Cancer Inst. 3;97(15):1162-3; author reply 1163-4.
    doi: 10.1093/jnci/dji216.
  22. Kunkler IH (2005). Rising healthcare costs, equity and electoral success constitute trio of tensions. BMJ. 16;330(7496):907. doi: 10.1136/bmj.330.7496.907-a.
  23. Kunkler IH (2004.) Circulating epithelial cells in breast cancer. New Engl J Med. 2;351(23):2452-4; author reply 2452-4.
  24. Kunkler IH (2004). Clinical standards. Lancet. 364:1400.
  25. Kunkler IH (2004). Network of Excellence. Lancet. 363:1554.
  26. Kunkler IH (2004). Adjuvant treatment of breast cancer with exemestane. New Eng J Med. 351:100.
  27. Kunkler IH, Prescott RJ, Williams L, King C (2004). Re: Breast-conserving surgery with or without radiotherapy: pooled analysis for risks of ipsilateral breast tumor recurrence and mortality. J. Nat Cancer Inst. 96:1255.
  28. Kunkler IH (2003). Non-commercial randomised clinical trials need money for meetings and travel expenses. BMJ. 327:1349.
  29. Kunkler IH (2003). Time has come for a medical minister of health. BMJ. 327:291.
  30. Kunkler IH (2003). Study showed only estimates of use of adjuvant radiotherapy. BMJ. 326:983.
  31. Kunkler IH, Jack W, Prescott R, Williams L, King C (2003). Postoperative breast irradiation: new trials needed in older patients. J Clin Oncol 21:1893.
  32. Kunkler IH (2003) Gene expression signatures in breast cancer. N Engl J Med. 348:1716.
  33. Kunkler IH (2003). Rethinking management. BMJ. 326:221.
  34. Kunkler IH (2002). In regard to Mose et al. Int J Rad Oncol Biol Phys. 53:786.
  35. Kunkler IH (2002). Radiotherapy for breast cancer. N Engl J Med. 346:862-4.
  36. Kunkler IH. (2002). Professionalism of doctors in the UK. Lancet. 359:530.
  37. Kunkler IH (2001). Radiotherapy units should be seen as shared resource in EU. BMJ. 323:1004.
  38. Kunkler IH, Collie D, Levack P, Grant R (2000). Dilemmas in cancer care. Lancet Oncology. 1:204. doi: 10.1016/s1470-2045(00)00146-7.
  39. Kunkler IH (2001). End of life decisions. Lancet. 357:640.
  40. Kunkler IH (2000). Breast-conserving surgery. Lancet. 357:305.
  41. Kunkler IH (2000). Adjuvant irradiation for breast cancer. BMJ. 321:1227.
  42. Camidge DR, Kunkler IH (2000). Docetaxel-induced radiation recall dermatitis and successful rechallenge. Clin Oncol. 12:272-3.
  43. Kunkler IH (2000). The future of oncology. Lancet. 355:500-1.
  44. Kunkler IH (2000). Quality of cancer services. Lancet. 355:1370.
  45. Kunkler IH (1999). NICE. J Roy Coll Phys London. 33:486.
  46. Kunkler IH (1999). Application of nuclear medicine. Lancet. 354:2002.
  47. Kunkler IH (1999). Sentinel lymph node biopsy in breast cancer. Lancet. 354:1998-9.
  48. Kunkler IH (1999). Postoperative radiotherapy in high-risk postmenopausal breast cancer. Lancet. 354:865.
  49. Kunkler IH (1999). Treatment of oral cancer: Radiotherapy may be as effective as surgery. BM.J 319:706.
  50. Kunkler IH (1999). Applications of nuclear medicine. Lancet. 354:2002.
  51. Kunkler IH (1999). Sentinel lymph node in breast cancer. Lancet. 354:1998.
  52. Kunkler IH (1999). Cancer survival in Britain. Perhaps Britain should adopt French model. BMJ. 319:1572.
  53. Kunkler IH (1999). Indications for post-mastectomy irradiation: do uncertainties remain? The Breast. 8:53-54.
  54. Kunkler IH (1998). European Breast Cancer meeting. Lancet. 351:1711.
  55. Kunkler IH (1998). Recommendations after RAGE litigation. Lancet. 352:657.
  56. Kunkler IH, Kerr G, Jack W (1997). Intensity of surveillance after breast conservation. J Clin Oncol.15:3420.
  57. Kunkler IH, Tierney A, Jodrell N (1997). Nurse practitioner led clinics. J Roy Soc Med. 90:586.
  58. Kunkler IH, Rafferty P, Henry M, Hill D, Foreman D (1997). Telemedicine: proved acceptable in pilot study in oncology in Scotland. BMJ. 314:521.
  59. Kunkler IH, Tierney A, Jodrell N, Forbes J (1996). Routine follow up of breast cancer in primary care. BM.J 313:1547-8.
  60. Kunkler IH (1996). Scottish randomised trial of conservation for breast cancer. Lancet. 348:1458-9.
  61. Makris A and Kunkler IH (1996). Controversies in the management of malignant spinal cord compression. Clin Oncol. 8:64.
  62. Kunkler IH (1994). Cancer of the upper gastrointestinal tract. Palliative chemotherapy unproven in advanced gastric cancer. BMJ. 308:1508-9.
  63. Kunkler IH, Chetty U, Rodger A (1994). Neurological symptoms may not be due to radiotherapy. BMJ. 308:715.

Kunkler IH (1992). Treating elderly patients with breast cancer. BMJ. 304:1377.


Medical Textbooks

  1. Bomford CK and Kunkler IH. Editors: Walter and Miller’s Textbook of Radiotherapy. 6th Edition, Elsevier Science (2002).
  2. The Effective Management of Breast cancer. Editors: Mansel R; Smith I, Kunkler IH, Miles A. UK Key Advances in Clinical Practice Series, Aesculapius Medical Press (2001). 
  3. Bomford CK, Kunkler IH and Sheriff S. Editors: Walter and Miller’s Textbook of Radiotherapy 5th Edition, Churchill Livingston (1993). 

Chapters in Medical Textbooks

  1. Kunkler IH. Breast Cancer. Walter and Miller’s Textbook of Radiotherapy. 9th Edition, Elsevier Science.2026
  2. Carol Ward, James Meehan, Mark Gray, Ian H. Kunkler, Simon P. Langdon, Alan Murray and David Argyle. (2021). Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment. Current Topics in Microbiology and Immunology. Volume 430. Springer 2021. Doi.org/10.1007/978-3-030-62452-1
     
  3. Kronowitz, S. J. (Ed.), Benson, J. R. (Ed.), Nava, M. B. (Ed.). (2020). Oncoplastic and Reconstructive Management of the Breast, Third Edition. Boca Raton: CRC Press, https://doi.org/10.1201/9781003005476
  4. Ward C, Meehan J, Gray M, Kunkler IH, Landon SP, Murray A, Argyle D (2019). Preclinical Organotopic Models for the Assessment of Novel Cancer Therapeutics and Treatment. Durr Top Microbiol Immunol March 12 doi: 10.1007/82_2019_159
  5. I Kunkler (2019). Breast Cancer in Walter and Miller’s Textbook of Radiotherapy. Editors: P. Symonds, Duxbury A, Mills J. 8th Edition, Elsevier, pp 399-443
  6. Marland, J. R. K., Blair, E. O., Flynn, B. W., González-fernández, E., Huang, L., Kunkler, I. H., Smith, S., Staderini, M., Tsiamis, A., Ward, C. & Murray, A. F (2017). Implantable Microsystems for Personalised Anticancer Therapy. CMOS Circuits for Biological Sensing and Processing. Mitra, S. & Cumming, D. R. S. (eds.). Springer International Publishing, 4 Nov, pp. 259-286 Chapter 11
  7. I Kunkler (2018). Oncologic consideration radiation oncologist in Oncoplastic and Reconstructive Surgery of the Breast. Taylor & Francis Group (in press).
  8. I Kunkler (2016). Ductal carcinoma in situ. 2nd Edition of Management of Breast Diseases, Springer (in press). 
  9. I Kunkler (2016). Personalized treatment of breast cancer. Springer
  10. I Kunkler (2013). The Role of palliative radiotherapy in breast cancer. Radiation Oncology in palliative Cancer Care, Wiley-Blackwell May 2013
  11. I Kunkler (2013). The role of adjuvant radiotherapy in the management of breast cancer. A companion to specialist surgical practice: Breast Surgery 5th Edition, Elsevier 15;242-257.
  12. I Kunkler (2013). Radiation therapy following breast conserving surgery (BCS) or mastectomy. Early Breast Cancer: From Screening to Multidisciplinary Management 3rd Edition, Informa Healthcare (in press).
  13. Kunkler IH (2012). Breast Cancer in: Walter and Miller’s Textbook of Radiotherapy. Symonds, Deeham and Meredith. 7th Edition, Elsevier Science 26: 431-466.
  14. I Kunkler (2012). Breast cancer. Cancer and Aging: Research and Practice, Wiley-Blackwell 18: 243-267.
  15. I Kunkler (2012). Radiotherapy in older patients. Cancer and Aging: Research and Practice, Wiley-Blackwell 17: 221-239.
  16. I Kunkler (2011). Radiotherapy for breast conserving surgery. Oncoplastic Breast-Conserving Surgery, Elsevier (in press).
  17. I Kunkler (2010). Postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer in The Local Management of Primary Breast Cancers, Kyoto University Press, pp 176-184.
  18. Kunkler IH (2008). The organisation of UK cancer services: a UK perspective. Treatment of Cancer. Price PM, Sikora K and Illidge T. Arnold, pp 1377-1406.
  19. Kunkler IH (2002). Epidemiology, prevention, early diagnosis and cancer education in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler, 6th Edition, Elsevier Science, pp 255-273.
  20. Kunkler IH (2002). Effects of ionising radiation on normal tissues in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 296-306.
  21. Kunkler IH (2002). Principles of management and dosage in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 307-323.
  22. Kunkler IH (2002). Skin and lip cancer in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 324-335.
  23. Kunkler IH (2002). Interstitial implantation in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 336-344.
  24. Kunkler IH (2002). Cancer of the mouth, secondary nodes of neck, tonsil, nasopharynx, paranasal sinuses, ear, salivary glands in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 345-377.
  25. Kunkler IH (2002). Lower pharynx, larynx, postcricoid, thyroid in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 378-399.
  26. Kunkler IH (2002). Cancer of the oesophagus, lung, thymus, gastrointestinal tract in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 400-431.
  27. Kunkler IH (2002). Cancer of the breast in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 432-464.
  28. Radstone DJ and Kunkler IH (2002). Cancer of the cervix and body of uterus, ovary, vagina, vulva, gestational trophoblastic disease in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, Elsevier Science, pp 465-486.
  29. Kunkler IH (2002). Central nervous system, eye and orbit. in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 537-563.
  30. Robinson MH and Kunkler IH (2002). Tumours of bone and soft tissue in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science pp 564-582.
  31. Kunkler IH (2002). Non malignant disorders in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 597-604.
  32. Kunkler IH (2002) Cancer chemotherapy in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 605-624.
  33. Kunkler IH (2002). Hormones and oncology in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler, 6th Edition, Elsevier Science, pp 625-632.
  34. Kunkler IH and Radstone DJ (2002). Palliative and continuing care in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 633-640.
  35. Kunkler IH and Kunkler AJ (2002). Quality of life in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford and IH Kunkler, 6th Edition, Elsevier Science, pp 641-647.
  36. Kunkler IH (2001). Evidentiary basis for radiotherapy following mastectomy as a major curative intervention. In UK Key Advances in Clinical Practice Series. Eds: Mansel R, Smith I, Kunkler I, Miles A. Aesculapius Medical Press, pp 53-63.
  37. Kunkler IH (2000). Treatment of the complications of radiotherapy for breast cancer. In: Dixon M and Sacchini V. Breast cancer: diagnosis and management. European School of Oncology.
  38. Kunkler IH and Jassem J (1998). Management of locally advanced breast cancer in: Management of Breast Cancer. Springer, Warsaw, pp 305-318.
  39. Kunkler IH and Goepel J (1993). Biological and pathological introduction in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 243-252.
  40. Kunkler IH and Robinson MH (1993). Tumours of bone and soft tissue in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler, 5th Edition, Churchill Livingstone, pp 243-252.
  41. Kunkler IH (1993). Principles of Radiobiology in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 253-264.
  42. Kunkler IH (1993). Effects of ionising radiation on normal tissues in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 265-274.
  43. Kunkler IH (1993). Principles of management and dosage in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 275-292.
  44. Kunkler IH (1993). Skin and lip cancer in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, 1993: 293-302.
  45. Kunkler IH (1993). Interstitial implantation in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 303-310.
  46. Kunkler IH and Manifold IH (1993). Cancer of the mouth, secondary nodes of neck, tonsil, nasopharynx, paranasal sinuses, ear salivary glands in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S. Sheriff. 5th Edition, Churchill Livingstone, pp 311-340.
  47. Kunkler IH and Manifold I H (1993). Lower pharynx, larynx, post-cricoid, thyroid in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff, 5th Edition, Churchill Livingstone, pp 341-360.
  48. Kunkler IH (1993). Cancer of the oesophagus, lung thymus, gastroinestinal tract in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 361-382.
  49. Kunkler IH (1993). Cancer of the breast in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 383-400.
  50. Kunkler IH (1993). Cancer of the cervix and body of uterus, ovary, vagina, vulva, gestational trophoblastic disease in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 401-422.
  51. Kunkler IH (1993). Cancer of the kidney, bladder, prostate, testis and penis in Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 423-442.
  52. Kunkler IH (1993). Lymphomas, leukaemias, myeloma, polycythaemic rubra vera in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 443-470.
  53. Kunkler IH (1993). Tumours of the central nervous system and eye in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, I Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 471-500.
  54. Kunkler IH and Manifold I H (1993). Tumours of bone and soft tissue in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 501-512.
  55. Kunkler IH (1993). Cancer in children in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, 1993: 513-520.
  56. Kunkler IH (1993). Non-malignant disorders in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, I Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 521-526.
  57. Kunkler IH (1993). Cancer chemotherapy in Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 527-544.
  58. Kunkler IH and Radstone D J (1993). Palliative and continuing care in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 551-558.
  59. Kunkler IH and Kunkler A J (1993). Quality of Life in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 559-564.
  60. Kunkler IH (1993). New Developments in Radiotherapy in: Walter and Miller’s Textbook of Radiotherapy. CK Bomford, IH Kunkler and S Sheriff. 5th Edition, Churchill Livingstone, pp 565-572.
  61. Kunkler IH (2017). Essentials Breast Cancer: Chapter 5, Radiotherapy.
  62. Kunkler IH, Ward C, Speers C, Pierce L, Feng F, Meehan J, Langdon S. Personalisation of radiotherapy for breast cancer. In:Personalized treatment of breast cancer. (Editors M Toi, Winer E, Benson J, Klimberg S). Springer, Japan 2016, pp 131-149.

Collaborations

  •  Professor David Cameron, The University of Edinburgh.
  •  Professor Mike Dixon, University of Edinburgh
  • Dr Niall Anderson, University of Edinburgh
  • Dr Linda Williams, University of Edinburgh
  • Dr Nicola Russell, Netherlands Cancer Institute
  • Professor Boon Chua, University of New South Wales, Sydney, Australia

Funders

  • UK MRC
  • NIHR
  • Breast Cancer Now

 

Scientific Themes

Clinical and translational breast cancer trials

Disease Areas

Breast Cancer

Technology Expertise

Radiotherapy

This article was published on